Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.
Integra LifeSciences Holdings Corporation reports developments as a global medical technology company focused on neurosurgery and tissue reconstruction. News commonly covers quarterly financial results, revenue guidance, operational execution, supply reliability, quality-management work and product availability across its medical technology portfolio.
Company updates also include clinical evidence and medical-conference activity for wound reconstruction products such as PriMatrix Dermal Scaffold, Integra Dermal Matrices, Cytal Wound Matrix, MicroMatrix and AmnioExcel. Recurring corporate topics include leadership appointments, investor conference presentations, manufacturing progress and segment activity within Codman Specialty Surgical and Tissue Technologies.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) hosted an Investor Day, highlighting expectations for Q2 2021 revenues between $372 million and $378 million, and adjusted EPS between $0.63 and $0.67. The company reaffirmed full-year guidance of $1,525 million to $1,535 million in revenue and adjusted EPS of $2.86 to $2.93. Long-term targets include 5% to 7% organic revenue growth and double-digit adjusted EPS growth. The company aims for adjusted gross margins of 70-72% and adjusted EBITDA margins of 28-30% by 2023.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) is set to host an Investor Day meeting on May 20, 2021, from 8:30 a.m. to approximately 12:30 p.m. U.S. Eastern Time. The event will be led by CEO Peter Arduini and the executive leadership team. Interested participants can preregister online and access a live webcast of the presentation on the company’s website. A replay will also be available post-event. Integra is recognized for its innovation in regenerative tissue technologies and neurosurgical solutions.
Integra LifeSciences (NASDAQ: IART) reported Q1 2021 revenues of $360.1 million, a 1.6% increase year-over-year. GAAP earnings per diluted share rose to $0.53 from $0.11 in Q1 2020. The company raised its 2021 revenue guidance by $5 million, targeting between $1,525 million and $1,535 million. Adjusted gross margin was 67.3%, down from 68.3% last year, influenced by revenue shifts and COVID-19 impacts. Adjusted EBITDA increased to $89.9 million, enhancing margins to 25.0%.
Integra LifeSciences (Nasdaq:IART) supports the FDA's recent safety communication regarding acellular dermal matrix (ADM) products in breast reconstruction. The company's SurgiMend Collagen Matrix is FDA-cleared for specific surgical applications but is not approved for breast reconstruction. Integra emphasizes the importance of patient-doctor discussions about medical technologies. The firm is dedicated to delivering safe and effective products and aims for future clearance for breast reconstruction applications, collaborating with healthcare professionals to enhance women's health.
Integra LifeSciences (NASDAQ: IART) announced its first quarter 2021 financial results will be released on April 28, 2021, prior to market open. The management will host a conference call at 8:30 a.m. ET for investors and analysts. Access will be through a dedicated phone line or a webcast on Integra's website. A replay of the call will be available until May 8, 2021. Integra specializes in regenerative tissue technologies and neurosurgical solutions, providing a wide range of medical products aimed at enhancing patient care.
Integra LifeSciences Holdings Corporation (Nasdaq:IART) has appointed Shaundra Clay to its board of directors as of April 1, 2021. Clay, a seasoned executive with extensive experience in finance and strategy, previously held significant roles at Beam Suntory, JP Morgan Chase, Eli Lilly, and Medtronic. Her expertise is expected to enhance the board's ability to drive financial performance. The announcement highlights the company’s commitment to strong corporate governance and strategic growth in the medical technology sector.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced its participation in several upcoming investor conferences. On February 24, 2021, CFO Carrie Anderson will present at the Citi 2021 Healthcare Services Conference at 2:25 pm ET. Following this, she will present at the Raymond James 42nd Annual Conference on March 3, 2021, at 7:30 am ET. Lastly, COO Glenn Coleman will speak at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 1:50 pm ET. Webcast details are available on their investor relations website.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported Q4 2020 revenues of $388.6 million, down 1.6% year-over-year, but up 5% sequentially. GAAP earnings per diluted share increased to $1.09, aided by a one-time tax benefit of $59.2 million. Full-year revenues fell 9.6% to $1,371.9 million due to COVID-19 impacts, despite a net income rise to $133.9 million. Cash flows from operations were robust at $203.8 million, with strong liquidity, holding $470.2 million cash. The company is optimistic about growth in 2021, focusing on enhancing operations and product portfolio.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) has completed the acquisition of ACell, Inc., enhancing its complex wound management solutions with proprietary MatriStem UBM™ technologies. CEO Peter Arduini emphasizes this acquisition will help address significant clinical challenges in wound care. The legal advisory for the transaction was handled by Sullivan & Cromwell LLP. Integra continues to focus on providing high-quality regenerative tissue technologies and neurosurgical solutions to improve patient care.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced its preliminary fourth quarter and full-year 2020 revenue results. The fourth quarter revenue is estimated between $387 million to $389 million, marking a decrease of up to 2.1% year-over-year. Full-year revenue is projected at $1,370 million to $1,372 million, reflecting a 9.7% decline. Despite these figures, the company indicated sequential improvement from Q3 and anticipates growth in 2021 following its recent divestiture of Extremity Orthopedics and acquisition of ACell. Financial results will be fully released on February 18, 2021.